Statistiche di base
| LEI | 254900GM24PT1FMTRP66 |
| CIK | 1531978 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Paragon 28, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| May 1, 2025 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-40902 Paragon 28, Inc. (Exact name of registrant as specified in |
|
| April 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on April 21, 2025 As filed with the U.S. Securities and Exchange Commission on April 21, 2025 Registration No. 333-268082 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-268082 UNDER THE SECURITIES ACT OF 1933 Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3170186 (State or other ju |
|
| April 21, 2025 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on May 02, 2025, pursuant to the provisions of Rule 12d2-2 (a). |
|
| April 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on April 21, 2025 As filed with the U.S. Securities and Exchange Commission on April 21, 2025 Registration No. 333-260367 Registration No. 333-270225 Registration No. 333-277586 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-260367 FORM S-8 REGISTRATION STATEMENT NO. 333-270225 FORM S-8 REGISTRATION STATEMENT NO. 333- |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COM MISS ION Washington, D.C. 20549 FORM 10-K (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-4 |
|
| April 21, 2025 |
Amended and Restated Certificate of Incorporation of Paragon 28, Inc., dated April 21, 2025 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PARAGON 28, INC. FIRST: The name of the corporation is PARAGON 28, INC. (the “Corporation”). SECOND: The address of the Corporation’s registered office in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The name of the Corporation’s registered agent at such |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 21, 2025 (April 17, 2025) Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40902 27-3170186 (State or other jurisdiction of incorporation) (C |
|
| April 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on April 21, 2025 As filed with the U.S. Securities and Exchange Commission on April 21, 2025 Registration No. 333-260367 Registration No. 333-270225 Registration No. 333-277586 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-260367 FORM S-8 REGISTRATION STATEMENT NO. 333-270225 FORM S-8 REGISTRATION STATEMENT NO. 333- |
|
| April 21, 2025 |
Exhibit 10.1 April 17, 2025 Via E-Mail [Albert DaCosta][Chadi Chahine] RE: Tax Gross-Up Agreement Dear [Albert][Chadi]: As you know, Paragon 28, Inc., a Delaware corporation (the “Company”), has entered into an Agreement and Plan of Merger, dated January 28, 2025 (the “Merger Agreement”), by and among the Company, Zimmer Inc., a Delaware corporation (“Parent”), Gazelle Merger Sub I, Inc., a Delawa |
|
| April 21, 2025 |
Amended and Restated Bylaws of Paragon 28, Inc., dated April 21, 2025 Exhibit 3.2 BYLAWS OF PARAGON 28, INC. ARTICLE I OFFICES SECTION 1. Registered Office. The registered office of Paragon 28, Inc. (the “Corporation”) shall be established and maintained at the office of Corporation Service Company, in the City of Wilmington, in the County of New Castle, in the State of Delaware, and said company shall be the registered agent of the Corporation in charge thereof. SE |
|
| April 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on April 21, 2025 As filed with the U.S. Securities and Exchange Commission on April 21, 2025 Registration No. 333-260367 Registration No. 333-270225 Registration No. 333-277586 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-260367 FORM S-8 REGISTRATION STATEMENT NO. 333-270225 FORM S-8 REGISTRATION STATEMENT NO. 333- |
|
| April 17, 2025 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2025 Paragon 28, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2025 Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-40902 (Commission File Number) 27-31 |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| March 18, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by R |
|
| March 11, 2025 |
Exhibit 99.1 Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act ENGLEWOOD, CO., March 11, 2025 - Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrus |
|
| March 11, 2025 |
false000153197814445 GRASSLANDS DRIVEENGLEWOOD00015319782025-01-282025-01-28false000153197800015319782025-03-102025-03-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 11, 2025 |
Press Release, dated March 11, 2025, issued by Paragon 28, Inc. Exhibit 99.1 Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act ENGLEWOOD, CO., March 11, 2025 - Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrus |
|
| March 11, 2025 |
Financial Statements and Exhibits, Other Events false000153197814445 GRASSLANDS DRIVEENGLEWOOD00015319782025-01-282025-01-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-409 |
|
| March 6, 2025 |
Paragon 28 Inc. Insider Trading and Disclosure Policy EXHIBIT 19.1 Paragon 28, Inc. Insider Trading Compliance Policy and Procedures Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this information to others who may trade. Violating su |
|
| March 6, 2025 |
Exhibit 21.1 LIST OF SUBSIDIARIES OF PARAGON 28, INC. as of December 31, 2024 Company Jurisdiction of Formation Paragon 28 Medical Devices Trading Limited1 Ireland Paragon 28 Australia PTY LTD2 Australia Paragon 28 DE Gmbh1 Germany Paragon 28 Italia SRL1 Italy Disior Oy1 Finland Paragon Advanced Technologies, Inc.1 Delaware Paragon 28 UK, LTD1 United Kingdom 1100% owned by Paragon 28, Inc. 2 100% |
|
| February 27, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) PARAGON 28, INC. |
|
| February 27, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Ru |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 29, 2025 |
false000153197800015319782025-01-282025-01-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| January 29, 2025 |
Exhibit 99.1 Zimmer Biomet: Media Investors Heather Zoumas-Lubeski 445-248-0577 [email protected] Kirsten Fallon 781-779-5562 [email protected] David DeMartino 646-531-6115 [email protected] Zach Weiner 908-591-6955 [email protected] Paragon 28: Media and Investors: Matt Brinckman 720-912-1332 [email protected] Zimmer Biomet Annou |
|
| January 29, 2025 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER By and Among ZIMMER, INC., GAZELLE MERGER SUB I, INC., PARAGON 28, INC. and, solely for purposes of Section 8.15, ZIMMER BIOMET HOLDINGS, INC. Dated as of January 28, 2025 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.01. The Merger 2 Section 1.02. Merger Closing 2 Section 1.03. Effective Time 3 Section 1.04. Effects of the Merge |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| January 29, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 28, 2025 Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-40902 (Commission File Number) 27- |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 29, 2025 |
Exhibit 99.1 Execution Version VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of January 28, 2025, is by and among Zimmer, Inc., a Delaware corporation (“Parent”), Gazelle Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and each of the undersigned stockholders (each, a “Stockholder”, and together the “Stockholders”) of the Com |
|
| January 29, 2025 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER By and Among ZIMMER, INC., GAZELLE MERGER SUB I, INC., PARAGON 28, INC. and, solely for purposes of Section 8.15, ZIMMER BIOMET HOLDINGS, INC. Dated as of January 28, 2025 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.01. The Merger 2 Section 1.02. Merger Closing 2 Section 1.03. Effective Time 3 Section 1.04. Effects of the Merge |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| January 29, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 28, 2025 Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-40902 (Commission File Number) 27- |
|
| January 29, 2025 |
Exhibit 99.1 Execution Version VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of January 28, 2025, is by and among Zimmer, Inc., a Delaware corporation (“Parent”), Gazelle Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and each of the undersigned stockholders (each, a “Stockholder”, and together the “Stockholders”) of the Com |
|
| January 29, 2025 |
false000153197814445 GRASSLANDS DRIVEENGLEWOOD00015319782025-01-282025-01-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| January 29, 2025 |
EX-99.(A) 2 ex99-a.htm JOINT FILING AGREEMENT Exhibit A JOINT FILING AGREEMENT The Undersigned agree that the statement on Schedule 13G with respect to the common stock of Paragon 28, Inc., dated as of January 29, 2025, is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under t |
|
| January 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 13, 2025 |
Exhibit 99.2 1 Note: Considered adding a 5th pillar of growth “Operational Excellence” where we highlight improvements to cash flow and margin, but think it will be better to include in a supplement or presentation later in the year J.P. Morgan 43rd Annual Healthcare Conference January 13, 2024 Presenters: Albert DaCosta (CEO & Chairman) Chadi Chahine (CFO and EVP of Supply Chain Operations) 2 Cop |
|
| January 13, 2025 |
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 Exhibit 99.1 Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 ENGLEWOOD, Colo. – January 13, 2025 (BUSINESS WIRE) – Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full |
|
| December 11, 2024 |
Paragon 28 Appoints Dave Demski to Board of Directors Exhibit 99.1 Paragon 28 Appoints Dave Demski to Board of Directors ENGLEWOOD, CO., December 11, 2024 — Paragon 28, Inc. (NYSE: FNA), (the “Company”) a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades o |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 12, 2024 |
Paragon 28 Reports Third Quarter 2024 Financial Results and Raises 2024 Net Revenue Guidance Exhibit 99.1 Paragon 28 Reports Third Quarter 2024 Financial Results and Raises 2024 Net Revenue Guidance ENGLEWOOD, CO., November 12, 2024 - Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue |
|
| November 12, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40902 Paragon 28, Inc. |
|
| October 11, 2024 |
October 11, 2024 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 Paragon 28, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 9, 2024 |
SC 13G 1 fna-sc13g073124.htm ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* Paragon 28, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 69913P105 (CUSIP Number) July 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| August 8, 2024 |
Exhibit 21.1 LIST OF SUBSIDIARIES OF PARAGON 28, INC. as of December 31, 2023 Company Jurisdiction of Formation Paragon 28 Medical Devices Trading Limited1 Ireland Paragon 28 Australia PTY LTD2 Australia Paragon 28 DE Gmbh1 Germany Paragon 28 Italia SRL1 Italy Disior Oy1 Finland Paragon Advanced Technologies, Inc.1 Delaware Paragon 28 UK, LTD1 United Kingdom 1100% owned by Paragon 28, Inc. 2 100% |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-4 |
|
| August 8, 2024 |
Paragon 28, Inc. Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 PARAGON 28, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Paragon 28, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of December 1, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy This Pol |
|
| August 8, 2024 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following descriptions of our capital stock and material provisions of our amended and restated certificate of incorporation (as amended, the “Certificate of Incorporation”) and our second amended and restated bylaws (the “Bylaws”) and of the Delaware General Corporation Law (the “DGCL”) are summaries and are qualified by reference to the amended and re |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 Paragon 28, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40902 Paragon 28, Inc. |
|
| August 8, 2024 |
Exhibit 99.1 Paragon 28 Appoints Chadi Chahine as Chief Financial Officer and Executive Vice-President of Supply Chain Operations, Reports Second Quarter 2024 Financial Results and Narrows 2024 Net Revenue Guidance ENGLEWOOD, CO., August 8, 2024 - Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, |
|
| August 8, 2024 |
Agreement dated August 5, 2024, by and between Chadi Chahine and the Company Exhibit 10.1 PARAGON 28, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), entered into as of the date of the last signature, between Paragon 28, Inc., a Delaware corporation (the “Company”) and Chadi Chahine (“Executive” and, together with the Company, the “Parties”). WHEREAS, the Company desires to assure itself of the services of Executive effective as of August 5, 2024 (su |
|
| August 8, 2024 |
1 2Q 2024 Earnings Update August 8, 2024 Exhibit 99.2 1 2Q 2024 Earnings Update August 8, 2024 2 Copyright ©2024 Paragon 28. All rights reserved. Forward Looking Statements Except for the historical information contained herein, the matters set forth in this document are forward - looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 , including, but not limited to : |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 Paragon 28, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 8, 2024 |
Paragon 28 Reports First Quarter 2024 Financial Results and Reaffirms 2024 Net Revenue Guidance Exhibit 99.1 Paragon 28 Reports First Quarter 2024 Financial Results and Reaffirms 2024 Net Revenue Guidance ENGLEWOOD, CO., May 8, 2024 — Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2024, and reaffirmed its 2024 net revenue gu |
|
| May 8, 2024 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 8, 2024 |
1Q 2024 Earnings Update May 8, 2024 Exhibit 99.2 Forward Looking Statements Except for the historical information contained herein, the matters set forth in this presentation are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28’s potential to shape a better future for foo |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40902 Paragon 28, Inc. |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 5, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 4, 2024 |
Agreement, dated April 3, 2024, by and between Kristina Wright and the Company. Exhibit 10.1 PARAGON 28, INC. INTERIM CFO CONSULTING AGREEMENT This Interim CFO Consulting Agreement (“Agreement”) is entered into as of April 3, 2024, (the “Effective Date”) by and between Paragon 28, Inc., a Delaware corporation (the “Company”) and Krissy Wright (“Consultant”). In consideration of the mutual promises contained in this Agreement, the parties agree as follows: 1. Services; Compens |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 4, 2024 |
Exhibit 99.1 Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024 • Stephen Deitsch resigns from his position as Chief Financial Officer to pursue another opportunity; Kristina Wright appointed interim Chief Financial Officer • Preliminary, unaudited first quarter 2024 net revenue expected to |
|
| March 1, 2024 |
As filed with the Securities and Exchange Commission on March 1, 2024 As filed with the Securities and Exchange Commission on March 1, 2024 Registration No. |
|
| March 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Paragon 28, Inc. |
|
| February 29, 2024 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 29, 2024 |
Exhibit 21.1 LIST OF SUBSIDIARIES OF PARAGON 28, INC. as of December 31, 2023 Company Jurisdiction of Formation Paragon 28 Medical Devices Trading Limited1 Ireland Paragon 28 Australia PTY LTD2 Australia Paragon 28 DE Gmbh1 Germany Paragon 28 Italia SRL1 Italy Disior Oy1 Finland Paragon Advanced Technologies, Inc.1 Delaware Paragon 28 UK, LTD1 United Kingdom 1100% owned by Paragon 28, Inc. 2 100% |
|
| February 29, 2024 |
Exhibit 99.1 Paragon 28 Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Net Revenue Guidance ENGLEWOOD, CO., February 29, 2024 – Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended December 31, 2023 and pro |
|
| February 29, 2024 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following descriptions of our capital stock and material provisions of our amended and restated certificate of incorporation (as amended, the “Certificate of Incorporation”) and our second amended and restated bylaws (the “Bylaws”) and of the Delaware General Corporation Law (the “DGCL”) are summaries and are qualified by reference to the amended and re |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40902 Paragon 28, Inc |
|
| February 29, 2024 |
Paragon 28, Inc. Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 PARAGON 28, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Paragon 28, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of December 1, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy This Pol |
|
| February 29, 2024 |
4Q and Full Year 2023 Update February 29, 2024 Exhibit 99.2 Forward Looking Statements Except for the historical information contained herein, the matters set forth in this presentation are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28’s potential to shape a better fut |
|
| February 14, 2024 |
FNA / Paragon 28, Inc. / DaCosta Albert - SC 13G/A Passive Investment SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Paragon 28, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69913P105 (CUSIP Number) D |
|
| February 13, 2024 |
FNA / Paragon 28, Inc. / MVM Partners, LLC - MVM PARTNERS LP FORM SC 13G Passive Investment SC 13G/A 1 mvmsc13ga.htm MVM PARTNERS LP FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Paragon 28, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 69913P105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statemen |
|
| February 13, 2024 |
EX-1 2 ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the statement on Schedule 13G with respect to the beneficial ownership by the undersigned of the Common Stock of Paragon 28, Inc., $0.001 par value per share, to which this Joint Filing Agreement is filed as an exhibit, has been filed on behalf of each of the undersigned, and that all subsequent am |
|
| January 8, 2024 |
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 Exhibit 99.1 Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 ENGLEWOOD, Colo. – January 8, 2024 (BUSINESS WIRE) – Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full |
|
| January 8, 2024 |
Exhibit 99.2 Note: Considered adding a 5th pillar of growth “Operational Excellence” where we highlight improvements to cash flow and margin, but think it will be better to include in a supplement or presentation later in the year J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 Presenters: Albert DaCosta (CEO & Chairman) Steve Deitsch (CFO) 1 Forward Looking Statements Except for the |
|
| January 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 8, 2023 |
Exhibit 10.1 PARAGON 28, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), entered into as of July 27, 2023, is between Paragon 28, Inc., a Delaware corporation (the “Company”) and Robert McCormack (“Executive” and, together with the Company, the “Parties”). WHEREAS, the Company desires to assure itself of the services of Executive effective as of August 14, 2023 (such date Ex |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40902 Paragon 28, Inc. |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 7, 2023 |
Paragon 28 Announces New $150 Million Credit Facility Replacing Existing $90 Million Credit Facility Exhibit 99.1 Paragon 28 Announces New $150 Million Credit Facility Replacing Existing $90 Million Credit Facility ENGLEWOOD, CO., November 7, 2023 - Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that it has received a new $150 million credit facility from Ares Capital Corporati |
|
| November 7, 2023 |
Exhibit 10.2 SECOND AMENDMENT TO BUSINESS LOAN AGREEMENT THIS SECOND AMENDMENT to Business Loan Agreement (this “Agreement”) is entered into to be effective as of the 2nd day of November, 2023 (the “Effective Date”), by and between PARAGON 28, INC., a Delaware corporation, as Borrower (“Borrower”), and ZIONS BANCORPORATION, N.A. DBA VECTRA BANK COLORADO, as Lender (“Lender”). RECITALS A) Borrower |
|
| November 7, 2023 |
Certain information has been omitted from this exhibit in places marked “[***]” because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. |
|
| November 7, 2023 |
3Q 2023 Update November 7, 2023 Exhibit 99.2 Forward Looking Statements Except for the historical information contained herein, the matters set forth in this presentation are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28’s potential to shape a better future for foot an |
|
| November 7, 2023 |
Paragon 28 Reports Third Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance Exhibit 99.1 Paragon 28 Reports Third Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance ENGLEWOOD, CO., November 7, 2023 — Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2023 and reaffirmed its 2023 net re |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2023 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 2, 2023 |
Paragon 28 Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance Exhibit 99.1 Paragon 28 Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance ENGLEWOOD, CO., August 2, 2023 - Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2023 and reaffirmed its 2023 net revenue |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40902 Paragon 28, Inc. |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 PARAGON 28, INC. (Exact name of registrant as specified in its charter) Delaware 001-40902 27-3170186 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 19, 2023 |
Second Amended and Restated Bylaws EX-3.2 3 d502180dex32.htm EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF PARAGON 28, INC. (a Delaware corporation) Effective May 17, 2023 TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BRO |
|
| May 19, 2023 |
Employment Agreement, effective as of April 18, 2022 by and between Paragon 28, Inc. and Jason Edie EX-10.1 Exhibit 10.1 PARAGON 28, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), entered into as of April 18, 2022 (the “Effective Date”), is between Paragon 28, Inc., a Delaware corporation (the “Company”) and Jason Edie (“Executive” and, together with the Company, the “Parties”). WHEREAS, the Company desires to assure itself of the continued services of Executive by engagi |
|
| May 19, 2023 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation of Paragon 28, Inc. EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PARAGON 28, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware The undersigned, for purposes of amending the Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), of Paragon 28, Inc. (the “Corporation”), a corporation or |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2023 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40902 Paragon 28, Inc. |
|
| May 4, 2023 |
Paragon 28 Reports First Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance Exhibit 99.1 Paragon 28 Reports First Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance ENGLEWOOD, CO., May 4, 2023 - Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2023 and reaffirmed its 2023 net revenue gui |
|
| April 7, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 6, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 27, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40902 Paragon 28, Inc |
|
| March 2, 2023 |
EXHIBIT 10.23 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant treats as private or confidential. Exhibit 10.23 Settlement Agreement This Settlement Agreement (the “Agreement”), effective as of November 28, 2022 (the “Effective Date”), is made by and between Wright |
|
| March 2, 2023 |
Power of Attorney (included in the signature page to this Registration Statement). S-8 As filed with the Securities and Exchange Commission on March 2, 2023 Registration No. |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 02, 2023 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 2, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Paragon 28, Inc. |
|
| March 2, 2023 |
Exhibit 21.1 LIST OF SUBSIDIARIES OF PARAGON 28, INC. as of December 31, 2022 Company Jurisdiction of Formation Paragon 28 Medical Devices Trading Limited Ireland Paragon 28 Australia PTY LTD Australia Paragon 28 Medical Devices Trading Limited South Africa Paragon 28 DE Gmbh Germany Paragon 28 Italia SRL Italy Disior Oy Finland Paragon Advanced Technologies, Inc. Delaware Paragon 28 UK, LTD Unite |
|
| March 2, 2023 |
Exhibit 99.1 Paragon 28 Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance ENGLEWOOD, CO., March 2, 2023 - Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended December 31, 2022. Fourth Quarter and Full Year |
|
| March 2, 2023 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following descriptions of our capital stock and material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws and of the Delaware General Corporation Law (the “DGCL”) are summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated bylaws |
|
| February 14, 2023 |
EX-1 2 ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the statement on Schedule 13G with respect to the beneficial ownership by the undersigned of the Common Stock of Paragon 28, Inc., $0.001 par value per share, to which this Joint Filing Agreement is filed as an exhibit, has been filed on behalf of each of the undersigned, and that all subsequent am |
|
| February 14, 2023 |
SC 13G/A 1 mvmsc13ga.htm MVM PARTNERS LP FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Paragon 28, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 69913P105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statemen |
|
| February 13, 2023 |
SC 13G/A 1 d451685dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Paragon 28, Inc. (Name of Issuer) Common Stock (Title of Class of Securiti |
|
| February 13, 2023 |
FNA / Paragon 28, Inc. Common Stock / DaCosta Albert - SC 13G/A Passive Investment SC 13G/A 1 d396545dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Paragon 28, Inc. (Name of Issuer) Common Stock (Title of Class of Securiti |
|
| January 30, 2023 |
EX-1.1 2 d420773dex11.htm EX-1.1 Exhibit 1.1 EXECUTION VERSION PARAGON 28, INC. (a Delaware corporation) 6,500,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: January 25, 2023 PARAGON 28, INC. (a Delaware corporation) 6,500,000 Shares of Common Stock UNDERWRITING AGREEMENT January 25, 2023 BofA Securities, Inc. Piper Sandler & Co. as Representatives of the several Underwriters c/o BofA Se |
|
| January 30, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 27, 2023 |
6,500,000 Shares Paragon 28, Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268082 PROSPECTUS SUPPLEMENT (to Prospectus dated November 7, 2022) 6,500,000 Shares Paragon 28, Inc. Common Stock We are offering 3,750,000 shares of our common stock and the selling securityholders identified in this prospectus supplement are offering 2,750,000 shares of our common stock. We will not receive any of the proce |
|
| January 25, 2023 |
SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT DATED JANUARY 25, 2023 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268082 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are n |
|
| January 25, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 12, 2023 |
FNA / Paragon 28, Inc. Common Stock / Bird B. AG - SC 13G Passive Investment SC 13G 1 d448177dsc13g.htm SC 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Paragon 28, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69 |
|
| January 10, 2023 |
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022 Exhibit 99.1 Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022 ENGLEWOOD, Colo. – January 10, 2023 (BUSINESS WIRE) – Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-yea |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 1, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 10, 2022 |
Paragon 28 Reports Third Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance Exhibit 99.1 Paragon 28 Reports Third Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance ENGLEWOOD, Colo., November 10, 2022 - Paragon 28, Inc. (NYSE: FNA) (?PARAGON?), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2022 and increased its 2022 net revenue guidance |
|
| November 10, 2022 |
Exhibit 10.3 FIRST AMENDMENT TO BUSINESS LOAN AGREEMENT THIS FIRST AMENDMENT to Business Loan Agreement (this ?Agreement?) is entered into to be effective as of the 10th day of November, 2022, by and between PARAGON 28, INC., a Delaware corporation, as Borrower (?Borrower?), and ZIONS BANCORPORATION, N.A. DBA VECTRA BANK COLORADO, as Lender (?Lender?). RECITALS A. Borrower and Lender are party to |
|
| November 10, 2022 |
Execution Version Exhibit 10.2 Limited waiver and amendment no. 4 to CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This LIMITED WAIVER AND AMENDMENT NO. 4 TO CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this ?Agreement?) is made as of the 9th day of November, 2022, by and among PARAGON 28, INC., a Delaware corporation (?Paragon 28?), Paragon Advanced Technologies, Inc., a Delaware corporation |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40902 Paragon 28, Inc. |
|
| November 10, 2022 |
Exhibit 10.1 limited waiver and amendment no. 3 to CREDIT AND SECURITY AGREEMENT (TERM LOAN) This LIMITED WAIVER AND AMENDMENT NO. 3 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this ?Agreement?) is made as of the 9th day of November, 2022, by and among PARAGON 28, INC., a Delaware corporation (?Paragon 28?), Paragon Advanced Technologies, Inc., a Delaware corporation (?Paragon Advanced Technolog |
|
| November 3, 2022 |
Paragon 28, Inc. 14445 Grasslands Drive Englewood, CO 80012 Paragon 28, Inc. 14445 Grasslands Drive Englewood, CO 80012 November 3, 2022 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Conlon Danberg Re: Paragon 28, Inc. Registration Statement on Form S-3 (Registration No. 333-268082) To the addressee set forth above: In a |
|
| November 1, 2022 |
Calculation of Filing Fee Table EX-FILING FEES 5 d399798dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Paragon 28, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate |
|
| November 1, 2022 |
EX-4.4 2 d399798dex44.htm EX-4.4 Exhibit 4.4 PARAGON 28, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Seri |
|
| November 1, 2022 |
Powers of Attorney (incorporated by reference to the signature page hereto) Table of Contents As filed with the Securities and Exchange Commission on November 1, 2022 Registration No. |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2022 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2022 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 3, 2022 |
Paragon 28 Reports Second Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance EX-99.1 2 fna-ex991.htm EX-99.1 Paragon 28 Reports Second Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance ENGLEWOOD, Colo., August 3, 2022 - Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2022 and increased its 2022 revenue |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40902 Paragon 28, Inc. |
|
| July 29, 2022 |
Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. |
|
| July 29, 2022 |
FNA / Paragon 28, Inc. Common Stock / Rosenthal Investment Company, LLC - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Paragon 28, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69913P105 (CUSIP Number) December 31 |
|
| May 20, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 9, 2022 |
Paragon 28 Reports First Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance Exhibit 99.1 Paragon 28 Reports First Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance ENGLEWOOD, Colo., May 9, 2022 - Paragon 28, Inc. (NYSE: FNA) (?PARAGON?), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2022 and updated its 2022 revenue guidance. Financial High |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40902 Paragon 28, Inc. |
|
| May 9, 2022 |
Exhibit 10.3 EXECUTION VERSION AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) This AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this ?Agreement?) is made as of the 24th day of March, 2022, by and among PARAGON 28, INC., a Delaware corporation (?Paragon 28?), PARAGON ADVANCED TECHNOLOGIES, INC., a Delaware corporation (?Paragon Advanced Technologies?, and Paragon Adva |
|
| May 9, 2022 |
Exhibit 10.1 BUSINESS LOAN AGREEMENT THIS BUSINESS LOAN AGREEMENT (hereinafter referred to as this ?Agreement?) is executed to be effective as of March 24, 2022, by and between ZIONS BANCORPORATION, N.A. dba VECTRA BANK COLORADO, its successors and assigns (?Lender?), and PARAGON 28, INC., a Delaware corporation (the ?Borrower?). Recitals A. Lender has agreed to make a term loan (the ?Loan?) to Bo |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2022 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 9, 2022 |
Exhibit 10.2 EXECUTION VERSION AMENDMENT NO. 3 TO CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This AMENDMENT NO. 3 TO CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this ?Agreement?) is made as of the 24th day of March, 2022, by and among PARAGON 28, INC., a Delaware corporation (?Paragon 28?), PARAGON ADVANCED TECHNOLOGIES, INC., a Delaware corporation (?Paragon Advanced Technologies?, and Pa |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 5, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 30, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 17, 2022 |
Exhibit 99.1 Foot & Ankle Specialists March 2022 http://www.enduringjourneys.com/uploads/https://www.sec.gov/Archives/edgar/data/1531978/000153949722000621/north-225.jpg 2 CONFIDENTIAL Except for the historical information contained herein, the matters set forth in this presentation are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigati |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2022 Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40902 27-3170186 (State or other jurisdiction of (Commission File Number) (I.R.S. E |
|
| March 8, 2022 |
Exhibit 99.1 Paragon 28 Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Net Revenue Guidance ENGLEWOOD, Colo., March 8, 2022 - Paragon 28, Inc. (NYSE: FNA) (?Paragon 28? or ?P28?), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and twelve months ended December 31, 2021. 202 |
|
| March 8, 2022 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Paragon 28, Inc., had common stock, $0.01 par value per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), and listed on the New York Stock Exchange under the trading symbol ?FNA.? DESCRIPTION O |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40902 Paragon 28, Inc |
|
| March 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 08, 2022 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 8, 2022 |
Contract to Buy and Sell Real Estate Exhibit 10.16 4 1 2 3 4 1 2 3 [NAVPOINT LOGO] NavPoint Real Estate Group, LLC Matt Call Ph: 720-420-7530 Fax: 720-240-0762 6 7 The printed portions of this form, except differentiated additions, have been approved by the Colorado Real Estate 8 Commission.(CBS3-5-19) (Mandatory 7-19) 9 THIS FORM HAS IMPORTANT LEGAL CONSEQUENCES AND THE PARTIES SHOULD CONSULT LEGAL 11 12 AND TAX OR OTHER COUNSEL BEF |
|
| February 11, 2022 |
FNA / Paragon 28, Inc. Common Stock / DaCosta Albert - SC 13G Passive Investment SC 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Paragon 28, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69913P105 (CUSIP Number) Dece |
|
| February 9, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the statement on Schedule 13G with respect to the beneficial ownership by the undersigned of the Common Stock of Paragon 28, Inc. |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Paragon 28, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 69913P105 (CUSIP Number) October 18, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| January 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 12, 2022 Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40902 27-3170186 (State or other jurisdiction of (Commission File Number) (I.R.S. |
|
| January 12, 2022 |
Exhibit 99.1 + 2016 Year Incorporated 20 Employees Helsinki Headquarters $18 Million Leading International Pre - Operative Planning Software Upfront Cash Payment $8 Million Potential Technology & Commercial Milestone Earnouts Preoperative Planning Software AI Technology Patient Specific Algorithms Patient Specific Implants + Instruments Laser Alignment 3d Printing & Modeling Navigation & Guidance |
|
| January 12, 2022 |
Exhibit 99.2 Paragon 28 Announces Acquisition of Disior Disior advances Paragon 28?s SMART 28TM strategy, providing a comprehensive 3D analytics and pre-operative planning platform, and will immediately accelerate internal research programs ENGLEWOOD, Colo. ? January 12, 2022 (BUSINESS WIRE) ? Paragon 28, Inc. (NYSE: FNA) (?Paragon 28? or ?P28?), a leading medical device company exclusively focuse |
|
| January 10, 2022 |
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021 Exhibit 99.1 Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021 ENGLEWOOD, Colo. ? January 10, 2022 (BUSINESS WIRE) ? Paragon 28, Inc. (NYSE: FNA) (?Paragon 28? or ?P28?), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-yea |
|
| January 10, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 23, 2021 Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40902 27-3170186 (State or other jurisdiction of (Commission File Number) (I.R.S |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2022 Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40902 27-3170186 (State or other jurisdiction of (Commission File Number) (I.R.S. |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40902 Paragon 28, Inc. |
|
| November 22, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 Paragon 28, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40902 27-3170186 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 22, 2021 |
Exhibit 99.1 Paragon 28 Reports Third Quarter 2021 Financial Results and Provides 2021 Fourth Quarter Net Revenue Guidance ENGLEWOOD, Colo., November 22, 2021 - Paragon 28, Inc. (NYSE: FNA) (?PARAGON?), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and nine months ended September 30, 2021. Financial Hi |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 PARAGON 28, INC. (Exact name of registrant as specified in its charter) Delaware 001-40902 27-3170186 (State or other jurisdiction of incorporation) (Commission File |
|
| October 20, 2021 |
As filed with the Securities and Exchange Commission on October 19, 2021 S-8 1 d238964ds8.htm S-8 As filed with the Securities and Exchange Commission on October 19, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PARAGON 28, INC. (Exact name of Registrant as specified in its charter) Delaware 27-3170186 (State or other jurisdiction of incorporation or or |
|
| October 20, 2021 |
2021 Employee Stock Purchase Plan Exhibit 99.3 PARAGON 28, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE 1 PURPOSE The Plan?s purpose is to assist employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company, and to help such employees provide for their future security and to encourage them to remain in the employment of the Company and its Subsidiaries. The Plan consists of two |
|
| October 20, 2021 |
2021 Incentive Plan of Paragon 28, Inc. Exhibit 99.2a PARAGON 28, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. DEFINITIONS As used in the Plan, the following words and phrases have the m |
|
| October 19, 2021 |
Amended and Restated Certificate of Incorporation of Paragon 28, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PARAGON 28, INC. Paragon 28, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: 1. The name of the Corporation is Paragon 28, Inc. The Corporation was originally incorporated under the name Paragon 28, Inc. by the fili |
|
| October 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2021 PARAGON 28, INC. (Exact name of registrant as specified in its charter) Delaware 001-40902 27-3170186 (State or other jurisdiction of incorporation) (Commission File |
|
| October 19, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF PARAGON 28, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR NOMIN |
|
| October 18, 2021 |
7,812,500 Shares Paragon 28, Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-259789 PROSPECTUS 7,812,500 Shares Paragon 28, Inc. Common Stock This is Paragon 28, Inc.?s initial public offering. We are selling 7,812,500 shares of our common stock. The initial public offering price for our common stock is $16.00 per share. Prior to this offering, there has been no public market for our common stock. Our |
|
| October 12, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 PARAGON 28, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [●], 2021 PARAGON 28, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENT [●], 2021 BofA Securities, Inc. Piper Sandler & Co. as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 Piper Sandler & Co. 8 |
|
| October 12, 2021 |
Form of Indemnification Agreement Exhibit 10.5 INDEMNIFICATION AND ADVANCEMENT AGREEMENT This Indemnification and Advancement Agreement (?Agreement?) is made as of , 20 by and between Paragon 28, Inc., a Delaware corporation (the ?Company?), and , [a member of the Board of Directors/an officer/an employee/an agent/a fiduciary] of the Company (?Indemnitee?). This Agreement supersedes and replaces any and all previous Agreements bet |
|
| October 12, 2021 |
October 12, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jane Park Laura Crotty Re: Paragon 28, Inc. Registration Statement on Form S-1, as amended File No. 333-259789 Dear Ms. Park and Ms. Crotty: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, |
|
| October 12, 2021 |
Certificate of Incorporation, currently in effect. Exhibit 3.3 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE DO HEREBY CERTIFY THAT THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF INCORPORATION OF ?PARAGON 28, INC.? FILED IN THIS OFFICE ON THE EIGHTH DAY OF OCTOBER, A.D. 2021, AT 12:48 O?CLOCK P.M. 6291660 8100F SR# 20213465636 Authentication: 204365471 Date: 10-08-21 You may verif |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Paragon 28, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3170186 (State or incorporationor organization) (IRS Employer Identification No.) 14445 Grasslands Drive Englewoo |
|
| October 12, 2021 |
As filed with the Securities and Exchange Commission on October 12, 2021 As filed with the Securities and Exchange Commission on October 12, 2021 Registration No. |
|
| October 12, 2021 |
Paragon 28, Inc. 14445 Grasslands Drive Englewood, CO 80112 Paragon 28, Inc. 14445 Grasslands Drive Englewood, CO 80112 October 12, 2021 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Ibolya Ignat, Lynn Dicker, Jane Park and Laura Crotty Re: Paragon 28, Inc. Registration Statement on Form S-1 (File No. 333-259789) Ladies and Gentlemen: In acco |
|
| October 8, 2021 |
Exhibit 10.14 PARAGON 28, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), entered into as of October 8, 2021 (the ?Effective Date?), is between Paragon 28, Inc., a Delaware corporation (the ?Company?) and Matthew Jarboe (?Executive? and, together with the Company, the ?Parties?). This Agreement supersedes in its entirety that certain employment offer letter agreement between |
|
| October 8, 2021 |
Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan Exhibit 10.10(a) PARAGON 28, INC. 2021 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Paragon 28, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2021 Incentive Award Plan, as may be amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?), an option to purchase the number of shares of the Company?s Common Stock (the ?Shares?), set forth below |
|
| October 8, 2021 |
Exhibit 10.13 PARAGON 28, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), entered into as of October 8, 2021 (the “Effective Date”), is between Paragon 28, Inc., a Delaware corporation (the “Company”) and Stephen M. Deitsch (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain employment offer letter agreement bet |
|
| October 8, 2021 |
Form of 2021 Employee Stock Purchase Plan Exhibit 10.11 PARAGON 28, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE 1 PURPOSE The Plan?s purpose is to assist employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company, and to help such employees provide for their future security and to encourage them to remain in the employment of the Company and its Subsidiaries. The Plan consists of two |
|
| October 8, 2021 |
EX-10.10B 9 d179970dex1010b.htm EX-10.10B Exhibit 10.10(b) PARAGON 28, INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Paragon 28, Inc., a Delaware corporation, (the “Company”), pursuant to its 2021 Incentive Award Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an award of restricted stock units (“Restricted |
|
| October 8, 2021 |
As filed with the Securities and Exchange Commission on October 8, 2021 Table of Contents As filed with the Securities and Exchange Commission on October 8, 2021 Registration No. |
|
| October 8, 2021 |
Form of Non-Employee Director Compensation Policy EX-10.9 6 d179970dex109.htm EX-10.9 Exhibit 10.9 PARAGON 28, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Paragon 28, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2021 Incentive Award Plan (the “Plan”) and shall be effective upon the date of the effectiveness of the registration statement on Form S-1 filed by the Comp |
|
| October 8, 2021 |
Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PARAGON 28, INC. Paragon 28, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is Paragon 28, Inc. The Corporation was originally incorporated under the name Paragon 28, Inc. by the fili |
|
| October 8, 2021 |
Exhibit 10.12 PARAGON 28, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), entered into as of October 8, 2021 (the ?Effective Date?), is between Paragon 28, Inc., a Delaware corporation (the ?Company?) and Albert DaCosta (?Executive? and, together with the Company, the ?Parties?). This Agreement supersedes in its entirety that certain employment offer letter agreement between |
|
| October 8, 2021 |
Form of 2021 Incentive Award Plan of Paragon 28, Inc. Exhibit 10.10 PARAGON 28, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. DEFINITIONS As used in the Plan, the following words and phrases have the m |
|
| October 8, 2021 |
Exhibit 3.5 AMENDED AND RESTATED BYLAWS OF PARAGON 28, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR NOMIN |
|
| October 8, 2021 |
Form of Common Stock Certificate Exhibit 4.2 DELAWARE SEAL PARAGON 28, INC. CORPORATE October 8, 2021 PG FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.01 PAR VALUE PER SHARE, OF Paragon 28, Inc. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate is not valid until countersigned by the Transfer Agent and registered b |
|
| October 5, 2021 |
FOIA Confidential Treatment Requested Under 17 C.F.R. § 200.83 650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +1.714.540.1235 Fax: +1.714.755.8290 www.lw.com FIRM / AFFILIATE OFFICES October 5, 2021 Beijing Boston Brussels Century City Chicago Dubai D?sseldorf Frankfurt Hamburg Hong Kong Houston London Los Angeles Madrid Milan Moscow Munich New York Orange County Paris Riyadh San Diego San Francisco Seoul Shanghai Silicon Valley Sing |
|
| September 29, 2021 |
As filed with the Securities and Exchange Commission on September 29, 2021 Table of Contents As filed with the Securities and Exchange Commission on September 29, 2021 Registration No. |
|
| September 29, 2021 |
List of subsidiaries of Paragon 28, Inc. EX-21.1 2 d179970dex211.htm EX-21.1 Exhibit 21.1 LIST OF SUBSIDIARIES OF PARAGON 28, INC. Paragon 28 Medical Devices Trading Limited—Ireland |
|
| September 29, 2021 |
CORRESP 1 filename1.htm 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM /AFFILIATE OFFICES September 29, 2021 Beijing Boston Brussels Century City Chicago Dubai Düsseldorf Frankfurt Hamburg Hong Kong Houston London Los Angeles Madrid Milan Moscow Munich New York Orange County Paris Riyadh San Diego San Francisco Seoul Shanghai Silicon Valley S |
|
| September 24, 2021 |
Exhibit 3.2 Colorado Secretary of State Date and Time: 07/14/2021 12:26 PM Document must be filed electronically. ID Number: 20101433852 Paper documents are not accepted. Fees & forms are subject to change. Document number: 20211643426 For more information or to print copies Amount Paid: $25.00 of filed documents, visit www.sos.state.co.us. ABOVE SPACE FOR OFFICE USE ONLY Articles of Amendment fil |
|
| September 24, 2021 |
As filed with the Securities and Exchange Commission on September 24, 2021 Table of Contents As filed with the Securities and Exchange Commission on September 24, 2021 Registration No. |
|
| September 24, 2021 |
Exhibit 10.6 INDUSTRIAL LEASE AGREEMENT (Triple Net) LANDLORD ABMAR GRASSLANDS, LLC, A Colorado Limited Liability Company TENANT Paragon 28, Inc., A Colorado Corporation BUILDING 14445 Grasslands Drive Englewood, CO 80112 INDUSTRIAL LEASE AGREEMENT This Industrial Lease Agreement (“Lease”) is made between Landlord and Tenant identified below and constitutes a lease of the Premises identified below |
|
| September 24, 2021 |
Employment Agreement, by and between Paragon 28, Inc. and Albert DaCosta, effective January 1, 2020. Exhibit 10.1 PARAGON 28, INC. PRESIDENT AND CHIEF EXECUTIVE OFFICE EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Paragon 28, Inc., 14445 Grasslands Dr., Englewood, Colorado 80112 (“P28”) and Albert DaCosta, *** (“Employee”), effective January 1, 2020. 1. Employee shall serve as President and Chief Executive Officer. Employee is a fiduciary and shall use his full time |
|
| September 24, 2021 |
EX-10.7 12 d179970dex107.htm EX-10.7 Exhibit 10.7 Execution Version CREDIT AND SECURITY AGREEMENT (TERM LOAN) dated as of May 6, 2021 by and among PARAGON 28, INC., and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and MIDCAP FINANCIAL TRUST, as Agent, and THE LENDERS FROM TIME TO TIME PARTY HERETO TABLE OF CONTENTS Page ARTICLE 1 - D |
|
| September 24, 2021 |
EX-10.8 13 d179970dex108.htm EX-10.8 Exhibit 10.8 Execution Version CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) dated as of May 6, 2021 by and among PARAGON 28, INC., and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and MIDCAP FINANCIAL TRUST, as Agent, and THE LENDERS FROM TIME TO TIME PARTY HERETO TABLE OF CONTENTS Page ARTICLE |
|
| September 24, 2021 |
Exhibit 4.3 PARAGON 28, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT This Amended and Restated Investor Rights Agreement (this “Agreement”) is dated as of July 28, 2020, and is between Paragon 28, Inc., a Colorado corporation (the “Company”), the individuals and entities listed on Exhibit A (each, an “Investor” and collectively, the “Investors”), and the individuals listed on Exhibit B (eac |
|
| September 24, 2021 |
Form of Award Agreement pursuant to Omnibus Stock Option and Award Plan Exhibit 10.4(a) Award Agreement For Nonqualified Stock Options Granted Under the Paragon 28, Inc. Omnibus Stock Option and Award Plan [, 20] To Paragon 28, Inc. (the “Corporation”) hereby grants you a Nonqualified Stock Option (the “Option”) to purchase shares of the Common Stock of the Corporation on the terms set forth in this Award Agreement and in the Paragon 28, Inc. Omnibus Stock Option and |
|
| September 24, 2021 |
Employment Agreement, by and between Paragon 28, Inc. and Matthew Jarboe, effective January 1, 2020. Exhibit 10.3 PARAGON 28, INC. CHIEF COMMERCIAL OFFICER EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Paragon 28, Inc., 14445 Grasslands Dr., Englewood, CO 80112 (“P28”) and Matthew Jarboe, *** (“Employee”) effective January 1, 2020. 1. Employee shall serve as Chief Commercial Officer. Employee is a fiduciary and shall use his full time to faithfully, with diligence, |
|
| September 24, 2021 |
Second Amended and Restated Certificate of Incorporation of the Company, currently in effect. Exhibit 3.1 Document must be filed electronically. Paper documents are not accepted. Fees & forms are subject to change. For more information or to print copies of filed documents, visit www.sos.state.co.us. Colorado Secretary of State Date and Time: 07/22/2020 07:48 AM ID Number: 20101433852 Document number: 20201621384 Amount Paid: $25.00 ABOVE SPACE FOR OFFICE USE ONLY Amended and Restated Arti |
|
| September 24, 2021 |
Exhibit 3.4 BYLAWS OF PARAGON 28, INC. ARTICLE I. Definitions Section 1. Definitions. In these Bylaws, unless otherwise specifically provided: (a) “Act” shall mean the Colorado Business Corporation Act, as the same now exists or may hereafter be amended. (b) “Articles of Incorporation” means the Articles of Incorporation of the Corporation and includes amended and restated Articles of Incorporatio |
|
| September 24, 2021 |
Exhibit 10.2 PARAGON 28, INC. CHIEF FINANCIAL OFFICER EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Paragon 28, Inc., 14445 Grasslands, Englewood, Colorado 80112 (“P28”) and Stephen M. Deitsch (“Employee”), effective September 28, 2020. 1. Employee shall serve as Chief Financial Officer. Employee is a fiduciary and shall use his full time to faithfully, with diligenc |
|
| September 24, 2021 |
Omnibus Stock Option and Award Plan Exhibit 10.4 PARAGON 28, INC. OMNIBUS STOCK OPTION AND AWARD PLAN ARTICLE I — PREAMBLE 1.1 The Paragon 28, Inc. Omnibus Stock Option and Award Plan is intended to secure for the Corporation, its Subsidiaries and its shareholders the benefits arising from ownership of the Corporation’s Common Stock by the employees of the Corporation and its Subsidiaries and by the directors of the Corporation, all |
|
| September 9, 2021 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| September 9, 2021 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| September 9, 2021 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| September 9, 2021 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| September 9, 2021 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| September 9, 2021 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| September 9, 2021 |
DRS/A 1 filename1.htm Table of Contents This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Confidential Draft Submission No. 2 submitted to the Securities and Exchange Commission on September 8, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. |
|
| September 9, 2021 |
PARAGON 28, INC. OMNIBUS STOCK OPTION AND AWARD PLAN ARTICLE I — PREAMBLE EX-10.4 5 filename5.htm Exhibit 10.4 PARAGON 28, INC. OMNIBUS STOCK OPTION AND AWARD PLAN ARTICLE I — PREAMBLE 1.1 The Paragon 28, Inc. Omnibus Stock Option and Award Plan is intended to secure for the Corporation, its Subsidiaries and its shareholders the benefits arising from ownership of the Corporation’s Common Stock by the employees of the Corporation and its Subsidiaries and by the directors |
|
| September 9, 2021 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| September 8, 2021 |
140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County September 8, 2021 Chicago Paris Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washington, D.C |
|
| August 2, 2021 |
DRS 1 filename1.htm Table of Contents This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. As confidentially submitted to the Securities and Exchange Commission on August 2, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTR |
